AstraZeneca to launch cancer drug Acalabrutinib under brand name Calquence
New Delhi: Drug firm AstraZeneca Pharma India on Thursday said it will launch its Acalabrutinib 100 mg capsules, used for treatment of various types of blood cancers, under the brand name ''Calquence'' in the country on October 21.Read also: AstraZeneca restarts COVID-19 vaccine trials in UKThe capsules are indicated for treatment of patients with mantle cell lymphoma (MCL) who have received...
Login or Register to read the full article
New Delhi: Drug firm AstraZeneca Pharma India on Thursday said it will launch its Acalabrutinib 100 mg capsules, used for treatment of various types of blood cancers, under the brand name ''Calquence'' in the country on October 21.
Read also: AstraZeneca restarts COVID-19 vaccine trials in UK
The capsules are indicated for treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and for treatment of patients with chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), AstraZeneca Pharma India said in a filing to the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd